Toronto-based BenchSci, which helps pharmaceutical firms accelerate research and development (R&D) using artificial intelligence (AI), has announced $95 million CAD in Series D funding.
BenchSci plans to use this capital to expand its AI-powered drug-discovery platform.
The round, which was led by Al Gore’s Generation Investment Management with support from existing BenchSci backers Inovia Capital, TCV, Golden Ventures, and F-Prime Capital, brings BenchSci’s total funding to $218 million. The fresh capital comes about 16 months after BenchSci closed $63 million in Series C financing.
In a statement, BenchSci co-founder and CEO Liran Belenzon hailed the company’s Series D round as “validation” of the work its team has done and the traction that BenchSci has generated with large pharma and biotech firms around the world.
Feature image courtesy BenchSci.
The post BenchSci closes $95-million CAD Series D to expand AI drug-discovery platform first appeared on BetaKit.